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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
iodine and contribution to normal cognitive development pursuant to 
Article 14 of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Specialised Nutrition Europe (formerly IDACE), submitted pursuant to Article 14 
of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, 
Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim 
related to iodine and contribution to normal cognitive development. The food constituent, iodine, which is the 
subject of the health claim, is sufficiently characterised. Contribution to normal cognitive development is a 
beneficial physiological effect for infants and young children. A claim on iodine and contribution to normal 
cognitive and neurological function in the general population has already been assessed with a favourable 
outcome. In addition, there is a large body of evidence indicating a crucial role for iodine in growth and 
development. The Panel notes the well established role of iodine in preventing iodine deficiency disorders such 
as retarded mental and physical development in children and adolescents, and impaired mental function and 
reduced cognitive capacity for people of all ages. The Panel concludes that a cause and effect relationship has 
been established between the dietary intake of iodine and contribution to normal cognitive development. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for 
authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the 
Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 
was asked to deliver an opinion on the scientific substantiation of a health claim related to iodine and 
contribution to normal cognitive development. 
The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
The food constituent that is the subject of the health claim is iodine, which is an essential nutrient and 
is measurable in foods by established methods. The Panel considers that iodine is sufficiently 
characterised. 
The claimed effect proposed by the applicant refers to the importance of iodine for normal cognitive 
development. The target population proposed by the applicant is infants and young children from 
birth to three years of age. The Panel considers that contribution to normal cognitive development is a 
beneficial physiological effect for infants and young children. 
A claim on iodine and contribution to normal cognitive and neurological function in the general 
population has already been assessed with a favourable outcome. In addition, there is a large body of 
evidence indicating a crucial role for iodine in growth and development. 
The Panel notes the well established role of iodine in preventing iodine deficiency disorders such as 
retarded mental and physical development in children and adolescents, and impaired mental function 
and reduced cognitive capacity for people of all ages. 
The Panel concludes that a cause and effect relationship has been established between the dietary 
intake of iodine and contribution to normal cognitive development. 
The following wording reflects the scientific evidence: “Iodine contributes to normal cognitive 
development”. 
The Panel considers that in order to bear the claim, follow-on formulae should comply with the 
criteria of composition of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally 
complete foods for special medical purposes intended for use by infants and nutritionally complete 
foods for special medical purposes other than those intended for use by infants should comply with 
the criteria of composition of these foods as laid down in Directive 1999/21/EC; processed cereal-
based foods for infants and young children should comply with the criteria of composition of these 
foods as laid down in Directive 2006/125/EC; other foodstuffs intended for infants and young 
children should provide at least 15 % of the reference values for nutrition labelling for foods intended 
for infants and young children as laid down in Directive 2006/141/EC. Such amounts can be easily 
consumed as part of a balanced diet. The target population is infants and children up to three years. A 
Tolerable Upper Intake Level for iodine has been established for children, and has been set at 
200 µg/day for children of 1-3 years of age. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children’s development and health in a Community list of 
permitted claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any supplementary information supplied by the applicant available to the European Food Safety 
Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 14/02/2008. 
 The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
 On 26/03/2008, during the validation process of the application, EFSA sent a request to the 
applicant asking it to provide missing information. 
 On 26/07/2013, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 17/10/2013. 
 During its meeting on 11/12/2013, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to iodine and 
contribution to normal cognitive development. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: iodine and contribution to normal 
cognitive development. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of iodine, a positive assessment of its safety, nor a decision on whether iodine is, or is not, 
classified as a foodstuff. It should be noted that such an assessment is not foreseen in the framework 
of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Specialised Nutrition Europe (formerly IDACE), 9-31 Avenue des 
Nerviens, 1040 Brussels, Belgium. 
Food/constituent as stated by the applicant 
According to the applicant, the food constituent for which the claim is made is iodine. 
Health relationship as claimed by the applicant 
According to the applicant, iodine has an essential role in the development of the nervous system of 
the fetus and the infant. Lack of iodine can lead to disturbances of fetal development, manifesting 
itself as cretinism or, in milder cases, mental retardation, goitre and growth impairment. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “iodine is important for 
cognitive development”. 
As equivalent alternative wordings, the applicant has also proposed: “iodine contributes to/is involved 
in/is important for/plays an important role for/is necessary for/participates to/is needed for/supports 
the (cognitive) development of/the (normal) function of senses/neural systems”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, the target population is infants and young children from birth to three 
years of age. 
According to the applicant, the quantity needed to achieve the claimed effect is: 
 For follow-on formulae, the content in iodine should be within the range set in Directive 
2006/141/EC. 
 For dietary foods for special medical purposes, the content in iodine should be within the 
range set in Directive 1999/21/EC. 
 For processed cereal-based foods and baby foods, the content in iodine should be within the 
range set in Directive 2006/125/EC. 
 For processed cereal-based foods and baby foods, the content in iodine should reach at least 
15 % of the Nutrient Reference Values set in Directive 2006/125/EC, i.e. 15 % of 70 μg per 
100 g or 100 ml or per serving, as reconstituted. 
 For foods intended for infants and young children other than follow-on formulae, processed 
cereal-based foods and baby foods, the content in iodine should reach at least 15 % of the 
Nutrient Reference Values set in Directive 2006/141/EC, i.e. 15 % of 80 µg per 100 ml 
product ready for use. 
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ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claim is iodine, which is an essential nutrient and 
is measurable in foods by established methods. 
Iodine occurs naturally in foods and is authorised for addition to foods (Annex I of Regulation (EC) 
No 1925/2006
5
, Annex I of Directive 2002/46/EC
6
, Annex III of Directive 2006/141/EC
7





). This evaluation applies to iodine naturally 
present in foods and those forms authorised for addition to foods (Annex II of Regulation (EC) No 
1925/2006, Annex II of Directive 2002/46/EC, Annex III of Directive 2006/141/EC, Annex IV of 
Directive 2006/125/EC, Directive 2001/15/EC). 
The Panel considers that the food constituent, iodine, which is the subject of the health claim, is 
sufficiently characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant refers to the importance of iodine for normal cognitive 
development. The target population proposed by the applicant is infants and young children from 
birth to three years of age. 
The Panel considers that contribution to normal cognitive development is a beneficial physiological 
effect for infants and young children. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in PubMed, HighWire and Scirus, using the search terms 
“iodine”, “growth”, “development”, “brain”, “mental”, “cognitive”, “infant”, “children” and “clinical 
studies”. Further pertinent references were searched for in the retrieved literature. The search 
focussed on randomised controlled trials and on reviews/pooled analyses/meta-analyses in the target 
population of the claim. In addition, one (mechanistic) animal study was included. 
The applicant identified three human studies (Bleichrodt et al., 1988; Cao et al., 1994; Choudhury and 
Gorman, 2003) and one animal study (Mitchell et al., 1998) as being pertinent to the health claim. In 
addition, the applicant indicated eight reviews (Kasper, 1987; Pharoah, 1993; Kretchmer et al., 1996; 
Suter, 2002; Black, 2003; Dunn, 2003; Verhoef et al., 2003; Thamm et al., 2007), three expert 
assessments (JHCI, 2003; SCF, 2003; EFSA NDA Panel, 2010) and three “other” references (Van den 
Briel et al., 2000; Zimmermann et al., 2006; Wijaya-Erhardt et al., 2007) as relevant for the claim. 
The Panel has already assessed a claim on iodine and contribution to normal cognitive and 
neurological function with a favourable outcome (EFSA NDA Panel, 2010). The target population 
was the general population. 
                                                     
5 Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of 
vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26–38. 
6 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of 
the Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51–57. 
7 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending 
Directive 1999/21/EC Text with EEA relevance. OJ L 401, 30.12.2006, p. 1–33. 
8 Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and 
young children. OJ L 339, 6.12.2006, p. 16–35. 
9 Commission Directive 2001/15/EC of 15 February 2001 on substances that may be added for specific nutritional purposes 
in foods for particular nutritional uses. OJ L 52, 22.2.2001, p. 19–25. 
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In addition, there is a large body of evidence indicating a crucial role for iodine in growth and 
development (Sadler et al., 1999; Garrow et al., 2000; WHO, 2001; IoM, 2002; Strain and Cashman, 
2009). A wide spectrum of iodine deficiency disorders has been observed, depending on the degree of 
deficiency and the life stage at which the deficiency occurs. These disorders include goitre, 
hypothyroidism and impaired mental function, including the most severe forms of endemic cretinism 
(congenital, severe, irreversible mental and growth retardation). Other symptoms of severe iodine 
deficiency disorders (arising from iodine deficiency in the fetus) include deaf-mutism, squint, 
disorders of stance and gait, and dry skin and swollen subcutaneous tissue (Delange, 2000; EVM, 
2003; WHO, 2007). 
The Panel notes the well established role of iodine in preventing iodine deficiency disorders such as 
retarded mental and physical development in children and adolescents, and impaired mental function 
and reduced cognitive capacity for people of all ages (WHO, 2001). 
The Panel concludes that a cause and effect relationship has been established between the dietary 
intake of iodine and contribution to normal cognitive development. 
4. Panel’s comments on the proposed wording 
The Panel considers that the following wording reflects the scientific evidence: “Iodine contributes to 
normal cognitive development”. 
5. Conditions and restrictions of use 
The Panel considers that in order to bear the claim: 
 follow-on formulae should comply with the criteria of composition of follow-on formulae as 
laid down in Directive 2006/141/EC; 
 nutritionally complete foods for special medical purposes intended for use by infants and 
nutritionally complete foods for special medical purposes other than those intended for use by 




 processed cereal-based foods for infants and young children should comply with the criteria 
of composition of these foods as laid down in Directive 2006/125/EC; 
 other foodstuffs intended for infants and young children should provide at least 15 % of the 
reference values for nutrition labelling for foods intended for infants and young children as 
laid down in Directive 2006/141/EC. 
Such amounts can be easily consumed as part of a balanced diet. The target population is infants and 
children up to three years. A Tolerable Upper Intake Level (UL) for iodine has been established for 
children, and has been set at 200 µg/day for children of 1-3 years of age (SCF, 2002). 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, iodine, which is the subject of the health claim, is sufficiently 
characterised. 
                                                     
10 Commission Directive 1999/21/EC of 25 March 1999 on dietary foods for special medical purposes. OJ L 91, 7.4.1999, 
p. 29–36. 
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 The claimed effect proposed by the applicant refers to the importance of iodine for normal 
cognitive development. The target population proposed by the applicant is infants and young 
children from birth to three years of age. Contribution to normal cognitive development is a 
beneficial physiological effect for infants and young children. 
 A cause and effect relationship has been established between the dietary intake of iodine and 
contribution to normal cognitive development. 
 The following wording reflects the scientific evidence: “Iodine contributes to normal 
cognitive development”. 
 In order to bear the claim, follow-on formulae should comply with the criteria of composition 
of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally complete foods 
for special medical purposes intended for use by infants and nutritionally complete foods for 
special medical purposes other than those intended for use by infants should comply with the 
criteria of composition of these foods as laid down in Directive 1999/21/EC; processed 
cereal-based foods for infants and young children should comply with the criteria of 
composition of these foods as laid down in Directive 2006/125/EC; other foodstuffs intended 
for infants and young children should provide at least 15 % of the reference values for 
nutrition labelling for foods intended for infants and young children as laid down in 
Directive 2006/141/EC. Such amounts can be easily consumed as part of a balanced diet. The 
target population is infants and children up to three years. The Tolerable Upper Intake Level 
has been set at 200 µg/day for children of 1-3 years of age. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on iodine and contribution to normal cognitive development pursuant to 
Article 14 of Regulation (EC) No 1924/2006 (Claim serial No: 0065_FR). February 2008. Submitted 
by Specialised Nutrition Europe (formerly IDACE). 
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